Echinacea (Echinacea purpurea / E. angustifolia / E. pallida)
Echinacea (purple coneflower) is a North American flowering herb sold in UK pharmacies and supermarkets as a traditional cold-and-flu remedy. UK MHRA registers most Echinacea products as Traditional Herbal Medicinal Products (THR) for "the symptomatic relief of the common cold and influenza-type infections" with a short-term use restriction (typically ≤10 days continuous). The most-trialled UK preparation is A. Vogel Echinaforce® (a fresh-herb tincture of Echinacea purpurea). The clinical evidence is genuinely mixed. The Cochrane systematic review (Karsch-Völk 2014, CD000530, PMID 24554461, 24 RCTs, n=4,631) found substantial trial heterogeneity — none of the 12 prevention comparisons reached statistical significance individually, although post-hoc pooling suggested a relative risk reduction of 10-20%. For treating established colds, only one of seven treatment trials showed significant benefit. The Cochrane conclusion: Echinacea products "have not been shown to provide benefits for treating colds, although it is possible there is a weak benefit from some Echinacea products". UK NICE CKS Common Cold pathway does not specifically include or recommend echinacea. Three practical safety points genuinely matter: 1. <strong>Asteraceae allergy is a hard contraindication.</strong> Echinacea is in the same plant family as ragweed, daisy, mugwort, marigold, chamomile, and feverfew. If you have a known allergy to any of these, do not take echinacea — severe reactions including anaphylaxis have been reported in sensitised individuals. 2. <strong>Autoimmune disease — precautionary avoidance.</strong> Theoretical immune-stimulation effect; evidence base is weak but UK conservative practice avoids echinacea in lupus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, autoimmune thyroid disease. Talk to your specialist. 3. <strong>Pregnancy + breastfeeding — UK THR-labelled products typically list as contraindications.</strong> Talk to your midwife if you've been taking echinacea and are uncertain about a specific product. Camden Medicals does NOT currently retail a single-active echinacea SKU. For UK consumers researching this space: a UK THR-registered E. purpurea product (Echinaforce or similar) is the controlled-quality route; check the species declaration on the label.
Camden Medicals editorial · Last reviewed 12 May 2026 · Next review November 2026
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- UK MHRA THR-registered echinacea preparations have product- specific dosing — typically 200-900 mg/day of standardised E. purpurea root extract, or 5-10 drops of E. purpurea fresh-herb tincture (Echinaforce-style) 3× daily. Trial protocols typically dose for 7-10 days at first cold-symptom onset.
- Top use evidence
- Strong
On this page
What it is
Echinacea (purple coneflower) is a genus of perennial herbaceous flowering plants in the Asteraceae family, native to central and eastern North American prairies and used historically by Plains Indigenous nations for a range of medicinal purposes before adoption into European herbal medicine in the late 19th and 20th centuries.
Three species are most commonly used in modern herbal preparations:
- Echinacea purpurea — the most widely cultivated species, with both root and aerial parts (leaf, stem, flower) used in commerce. Constituents include alkamides (chiefly dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide and related), cichoric acid (a caffeic acid derivative), polysaccharides, and glycoproteins. The fresh-herb pressed-juice preparation (A. Vogel Echinaforce®) is the most-trialled UK product.
- Echinacea angustifolia — narrower-leaved species; predominantly root used. Higher alkamide content than E. purpurea root; lower cichoric acid. Some traditional Native American uses are specific to this species.
- Echinacea pallida — pale-flowered species, predominantly root used. Different chemotype again — contains echinacoside (not present in E. purpurea) and ketoalkenes / ketoalkynes.
The three species are not directly interchangeable. UK trial evidence is concentrated on specific E. purpurea preparations (Echinaforce, Esberitox® combinations); other species have smaller trial bases. Commercial preparations frequently combine multiple species without disclosing the proportions, and consumer-facing labelling sometimes omits the species declaration entirely — both practices undermine trial-comparable supplementation.
UK MHRA Traditional Herbal Registration (THR) products contain standardised extracts of one or more echinacea species. Standardisation markers vary: cichoric acid % (E. purpurea aerial parts), alkamide % (E. purpurea root, E. angustifolia root), echinacoside % (E. pallida and E. angustifolia root). The THR scheme registers products on safety and quality and traditional use — not on efficacy evidence as required for a Marketing Authorisation.
Echinacea preparations also include tinctures, dried herb teas, lozenges, sprays, and combination products with elderberry, propolis, vitamin C, zinc, or other immune-cluster ingredients.
At a glance
- UK MHRA THR-registered traditional herbal medicinal product for "symptomatic relief of the common cold and influenza-type infections" — short-term use ≤10 days. Three species: Echinacea purpurea (most common), E. angustifolia, E. pallida — different chemotypes, not interchangeable.
- Cochrane review (Karsch-Völk 2014 PMID 24554461, 24 RCTs n=4,631) — mixed evidence with substantial heterogeneity. Prevention comparisons individually non-significant; post-hoc pooling suggests 10-20% RR reduction. Treatment of established colds: only 1 of 7 trials showed benefit. Most-trialled UK product: A. Vogel Echinaforce® (E. purpurea fresh-herb tincture).
- CRITICAL CONTRAINDICATION: Asteraceae family allergy (ragweed, daisy, mugwort, marigold, chamomile, feverfew). Severe reactions including anaphylaxis have been reported.
- Precautionary contraindication: autoimmune disease (lupus, RA, MS, type 1 diabetes, autoimmune thyroid). Theoretical immune-stimulation; UK conservative practice avoids.
- Pregnancy / breastfeeding: UK THR-labelled echinacea products typically list pregnancy and breastfeeding as contraindications. Talk to midwife.
- UK NICE CKS Common Cold pathway: rest, hydration, paracetamol / ibuprofen for symptoms; specific antiviral medication NOT routinely indicated for uncomplicated viral upper-respiratory infections.
What people use it for
Adults wanting traditional symptomatic relief at the first sign of a cold
UK MHRA THR-registered echinacea preparations may be marketed for "symptomatic relief of the common cold and influenza-type infections" on a short-term basis (typically ≤10 days continuous). Cochrane review evidence is mixed — some preparations may produce modest reductions in cold incidence or duration; many trials show no effect. A. Vogel Echinaforce® (E. purpurea fresh-herb tincture) has the largest UK trial base. UK NHS pathway for the common cold is rest, fluids, simple analgesia, and self-limiting course over 7-10 days; echinacea is one of several traditional adjuncts available without prescription. UK NICE CKS Common Cold pathway does not list echinacea. [5,1]
Popular, not provenMixedAdults considering echinacea for chronic / prophylactic immune support
Echinacea is registered for short-term acute use, NOT for chronic / prophylactic supplementation. Some trials have explored prophylactic dosing but THR registrations include short-term-use restrictions. Marketing for chronic / "daily immune support" is outside THR scope and outside the bulk of the trial evidence.
Popular, not provenInsufficientAdults with diagnosed Asteraceae allergy or ragweed hay fever
AVOID echinacea. Cross-reactivity with the Asteraceae plant family (ragweed, daisy, mugwort, marigold, chamomile, feverfew) is the principal allergy concern. Severe reactions including anaphylaxis have been reported. [3]
Some evidenceStrongAdults with diagnosed autoimmune disease (lupus, rheumatoid arthritis, MS, type 1 diabetes, autoimmune thyroid disease)
Conservative practice is to avoid echinacea on the basis of theoretical immune-stimulation effect that could (in principle) exacerbate autoimmune disease activity. The evidence base is weak — formal RCTs in autoimmune populations have not been done, and the in-vitro and animal-model "immunomodulation" picture is more nuanced than uniform stimulation. Disclose any echinacea use to the rheumatology, neurology, or endocrinology team managing your condition.
Popular, not provenInsufficientAdults on immunosuppressant medication (transplant patients, biologic DMARDs, ciclosporin)
AVOID. Theoretical antagonism of immunosuppressant effect; risk of transplant rejection or autoimmune-disease activation. Disclose any supplement use to the prescribing team.
Some evidenceLimitedPregnant or breastfeeding women, or women trying to conceive
Avoid concentrated supplement extracts. Tea-tier consumption has historical use but THR labelling typically lists pregnancy and breastfeeding as contraindications. Talk to your midwife if uncertain. [8]
Some evidenceLimited
How it works
Echinacea's traditional immune-supportive effect is attributed to multiple constituent classes acting on different elements of the innate immune system. The mechanism picture is more complex than a single "immune booster" framing suggests.
Alkamides — cannabinoid CB2 receptor and macrophage modulation. The dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide and related alkamides are agonists at the CB2 cannabinoid receptor (the predominantly peripheral cannabinoid receptor expressed on immune cells) at sub-micromolar concentrations. CB2 activation modulates macrophage cytokine release (typically anti-inflammatory direction) and dendritic-cell function. Alkamides also have direct effects on neutrophil and macrophage function in cell-biology assays.
Cichoric acid — caffeic acid derivative with antioxidant and modest antiviral activity. Cichoric acid (the principal phenolic in E. purpurea aerial parts) has antioxidant capacity and modest in-vitro antiviral activity against influenza and rhinovirus. Whether the in-vitro antiviral effect translates to clinical antiviral activity at oral food-supplement doses is debated.
Polysaccharides and glycoproteins — innate immune signalling. High-molecular-weight polysaccharides from echinacea bind macrophage Toll-like receptors and pattern-recognition receptors, producing modest macrophage activation in cell-biology assays. The polysaccharide content is heat-labile and varies substantially between extraction methods (aqueous vs ethanolic; fresh-herb juice vs dried-root extract).
The "immune booster" framing oversimplifies. What the cell-biology and animal-model data show is modulation across several immune-system axes — cytokine release, macrophage activation, NK-cell function, neutrophil chemotaxis — not a uniform "boost". The clinical translation in human RCTs is modest reduction in upper-respiratory symptom severity and/or duration in some trials, no effect in others. Marketing language framing echinacea as turning up an immune-system thermostat is not consistent with what the literature actually shows.
Onset. Echinacea trial protocols typically dose at first cold symptom onset and continue for 7-10 days. Prophylactic chronic dosing is not the trial-evidenced use; the THR registration and Cochrane trial pool are concentrated on acute / short-term use.
Common myths
Myth""Echinacea boosts your immune system.""
RealityUK marketing for echinacea cannot make immune-system claims — EFSA's Article 13 evaluation of botanical immune claims is on hold. The in-vitro and animal-model picture shows modulation across several immune-system axes rather than uniform "boost". Clinical translation in trials is modest reduction in cold symptom severity / duration in some preparations, no effect in others. Marketing language framing echinacea as a thermostat-style "boost" is not consistent with the literature. [5]
Myth""Echinacea cures the cold.""
RealityIt does not. The common cold is a self-limiting viral illness with a 7-10 day natural history. Trial evidence supports modest reductions in symptom severity / duration with some echinacea preparations — not a remedy and not a prevention intervention for clinical consequence. UK NHS pathway is rest, fluids, paracetamol / ibuprofen for symptoms. [1]
Myth""All echinacea products are equivalent.""
RealityThree species (E. purpurea, E. angustifolia, E. pallida) with different chemotypes and different traditional uses; different plant parts (root vs aerial); different extraction methods (fresh-herb pressed juice, dried-herb tincture, dried-herb capsule, aqueous tea); different dosing protocols. UK trial evidence is concentrated on specific preparations (notably Echinaforce E. purpurea fresh-herb pressed-juice tincture). Generic "echinacea 1000 mg" tells you nothing about trial-comparability.
Myth""Echinacea is fine to take long-term as a daily preventative.""
RealityUK MHRA THR registrations restrict echinacea to short-term use (typically ≤10 days continuous, ≥3 weeks rest before re-starting). The clinical-trial pool is concentrated on acute / short-term use. Long-term daily use is not the trial- evidenced pattern; the precautionary autoimmune-disease consideration is also amplified by chronic use.
Myth""Echinacea is hypoallergenic — it's natural.""
RealityAsteraceae allergy is the principal allergy concern. Severe reactions including anaphylaxis have been reported in sensitised individuals. Naturalness-as-safety arguments do not apply. Cross-reactivity with ragweed hay fever, chamomile, marigold, daisy, feverfew is documented. [3]
What people say online
Echinacea discourse on TikTok and Reddit clusters around three narratives: "echinacea boosts immunity" (overstated relative to evidence); "natural cold remedy that works" (mixed evidence); and "safe for everyone" (Asteraceae allergy + autoimmune contraindications are real and load- bearing). This section surfaces the discourse without naming individuals.
Trending claims
- TikTok #immunity + r/Supplementshigh visibility
Claim: Echinacea boosts your immune system
Reality check: Cochrane evidence (Karsch-Völk 2014 PMID 24554461) is mixed — none of the 12 prevention comparisons reached statistical significance individually; post-hoc pooling suggested only 10-20% RR reduction. "Boosts your immune system" is not authorised wording under UK NHC register and is broader than the actual modest evidence base. UK NICE CKS Common Cold does not include echinacea. [7]
- TikTok + r/wintercoldsmedium visibility
Claim: Take echinacea daily through winter for cold prevention
Reality check: UK MHRA THR labelling specifies short-term use only — typically ≤10 days continuous. Sustained daily use through winter is outside the labelling and outside the Cochrane evidence base. Talk to your GP or pharmacist about your specific cold-prevention strategy.
- TikTok + alternative-medicine Redditmedium visibility
Claim: Echinacea is safe for everyone — it's natural
Reality check: Inaccurate. Asteraceae plant-family allergy (ragweed, daisy, mugwort, marigold, chamomile, feverfew) is a hard contraindication; severe reactions including anaphylaxis have been reported. Autoimmune disease (lupus, RA, MS, type 1 diabetes, autoimmune thyroid) is a precautionary contraindication on the basis of theoretical immune-stimulation effect. Pregnancy and breastfeeding are UK THR-labelled contraindications.
- TikTok + r/supplementstackhigh visibility
Claim: Echinacea + zinc + vitamin C is the natural cold remedy
Reality check: Each component has its own evidence base — zinc lozenges have modest evidence for reducing cold duration when started at first symptom (Camden zinc), vitamin C has mixed evidence (Hemilä Cochrane), and echinacea has mixed evidence (Karsch-Völk 2014). The combination has no specific synergy trial body. UK NICE pathway is symptomatic management. [7]
Where the conversation lives
- TikTok hashtags: #echinacea, #coldremedy, #immunity, #wintercolds, #naturalremedies
- Reddit subs: r/Supplements, r/wintercolds, r/herbalism, r/Allergies
- Forums: A. Vogel UK community, Examine.com (paid evidence comparator)
Questions people are searching
- Which Echinacea species is best?
- Does echinacea really work for colds?
- Can I take echinacea daily through winter?
- Is echinacea safe if I have lupus / RA / MS?
- Is echinacea safe in pregnancy?
- Echinacea or elderberry for the kids?
Who drives the discourse: The discourse is driven by four creator classes: herbal- medicine creators (the THR-tier wisdom — generally accurate when surfacing the species-identification + short-term-use framing); cold-and-flu creators (the "natural remedy" framing — Cochrane evidence is genuinely mixed); allergy / autoimmune patient creators (the contraindication awareness — load-bearing); and "natural-is-safe" wellness creators (the inaccurate "safe for everyone" framing). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Echinacea (Echinacea purpurea / E. angustifolia / E. pallida). Each answer is editorial and links to its evidence in the Sources list below.
How quickly do I need to start echinacea after I notice cold symptoms?
Trial protocols typically dose at first symptom onset and continue 7-10 days. The earlier the start, the more trial- comparable the use. Starting day 4 of an established cold is outside the trial pattern; the cold is self-limiting and will resolve on its own course over 7-10 days. [5]
Echinacea drops or capsules — which?
Trial evidence is concentrated on specific preparations rather than form. A. Vogel Echinaforce® (E. purpurea fresh-herb pressed-juice tincture, drops or tablets) has the largest UK trial base. Generic echinacea capsules without species or standardisation declaration are not trial-comparable. Read the label.
Can I take echinacea with my flu jab?
No specific contraindication. Annual influenza vaccination is the UK NHS-recommended prevention intervention for eligible groups. Echinacea is not a substitute for the flu jab. [2]
I have rheumatoid arthritis — should I avoid echinacea?
Conservative practice is to avoid echinacea in autoimmune disease (lupus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, autoimmune thyroid disease). The evidence base is weak but the theoretical immune-modulation concern plus the methotrexate / biologic DMARD interaction pattern warrants a precautionary position. Disclose any supplement use to the rheumatology team.
My child has a cold — can I give echinacea?
UK MHRA THR registrations for echinacea typically exclude children under 12 (some restrict to ≥18 years). Self- supplementing a child for cold symptoms with echinacea is not the appropriate pathway. UK NHS pathway is rest, fluids, paracetamol / ibuprofen for symptoms. Talk to your GP or pharmacist if unsure. [1]
⚖️ The official position
What may lawfully be claimed about Echinacea (Echinacea purpurea / E. angustifolia / E. pallida) in Great Britain. This is a regulatory position, not an evidence grade.
No health claim is authorised for this use in Great Britain.
Echinacea (Echinacea purpurea / E. angustifolia / E. pallida) has a history of traditional use. Authorised health claims require a positive EFSA scientific opinion; none has been issued for this use.
UK regulatory landscape
UK regulatory tier: Borderline / case-by-case
Echinacea sits at the food-supplement / Traditional Herbal Medicinal Product (THR) boundary in UK regulation. Higher- strength preparations with cold-and-flu indication wording require UK MHRA THR registration ("symptomatic relief of the common cold and influenza-type infections" — based on traditional use ≥30 years EU including ≥15 years UK). Lower-strength echinacea sold as food supplement cannot carry the THR indication wording; EFSA Article 13 botanical immune claims are on hold. Long history of EU food and herbal-medicine use predates 15 May 1997 — NOT a novel food.
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing as a cold / flu treatment without MHRA THR registration | |
| Marketing for autoimmune disease "support" or treatment | |
| Marketing for sustained / chronic daily prophylactic use beyond THR ≤10 days continuous | |
| Marketing without Asteraceae allergy + autoimmune disease + pregnancy contraindication disclosure | |
| Sale to children under 12 without paediatric-specific MHRA registration |
Permitted claims
UK MHRA THR-registered echinacea products carry the registered indication "for the symptomatic relief of the common cold and influenza-type infections" — based on traditional use ≥30 years EU including ≥15 years UK. NO Article 13.1 health claim is authorised under EU NHC regulation; EFSA evaluations on hold. Generic factual description for food-supplement-tier echinacea is permitted.
Cross-jurisdiction note
Echinacea is widely used in herbal medicine across the EU, UK, North America, and increasingly in Asia. UK MHRA THR framework + EMA HMPC monograph apply across the EU. US FDA classifies echinacea as a dietary supplement under DSHEA with no specific health claim authorisation. Health Canada has a Natural Health Product registration framework with specific echinacea monographs.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Common cold — incidence and duration in adults
MixedEvidencemixedCochrane review (Karsch-Völk 2014, CD000530.pub3) pooled 24 RCTs and concluded the evidence base is heterogeneous. Some E. purpurea preparations may produce modest reductions in cold incidence (10-20% relative risk reduction in pooled estimates) and duration (~1 day shorter in some trials). Many trials show no effect. Trial heterogeneity is substantial: different species, different plant parts, different extract methods, different dosing protocols, different cold-symptom outcome measures. UK NICE CKS Common Cold pathway does not list echinacea. The trial-evidence picture has not materially changed since the 2014 Cochrane review. [5,4]
Upper respiratory tract infection — children
InsufficientEvidenceinsufficientTrial evidence in children is small and inconsistent. UK MHRA THR registrations typically restrict paediatric use; some products are registered for ≥12 years, others ≥18 years. Self-supplementation in young children is not the appropriate pathway.
Influenza prevention or treatment
InsufficientEvidenceinsufficientTrial evidence for influenza-specific endpoints (laboratory- confirmed influenza, hospitalisation, mortality) is small and does not support echinacea as an influenza prevention or treatment. UK NHS pathway for suspected influenza is supportive care + (where indicated) antiviral medication via GP. Annual influenza vaccination is the UK NHS-recommended prevention intervention for eligible groups. [2]
Recurrent infections / "low immunity" framing
InsufficientEvidenceinsufficientRecurrent or unusually severe infection is a clinical pattern warranting GP investigation (immunological workup, not herbal supplementation). Echinacea is not a UK-recognised pathway for this presentation. UK NHS clinical pathway is GP review.
Autoimmune disease — risk of exacerbation
InsufficientEvidenceinsufficientTheoretical concern based on in-vitro immune-modulation; case reports of autoimmune-flare timing-association have been published but causality is uncertain. Conservative practice avoids echinacea in autoimmune disease pending better data.
Effect matrix — per-condition evidence
Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.
| Outcome | Population | Dose | Duration | Evidence | Direction | Sources |
|---|---|---|---|---|---|---|
| Common cold — prevention (incidence) | general | — | 4–16 wk | LimitedEvidencelimited | mixed | PMID 24554461 |
| Cochrane Karsch-Völk 2014 PMID 24554461 — 10 prevention trials with 12 comparisons. None of 12 prevention comparisons reported statistically significant individual cold-incidence reduction. Pooled post-hoc analysis showed 10-20% RR reduction. Cochrane conclusion: "weak benefit possible". Heterogeneous extracts (E. purpurea, E. angustifolia, E. pallida; aerial vs root) limit between-product generalisability. | ||||||
| Common cold — treatment of established symptoms (duration) | general | — | 1–2 wk | InsufficientEvidenceinsufficient | mixed | PMID 24554461 |
| Cochrane Karsch-Völk 2014 — of 7 treatment trials reporting cold duration, only 1 showed significant benefit. VERY_LIMITED / mixed honestly reflects the data. UK NHS pathway: symptomatic relief, no antibiotic for viral URTI; echinacea not in NICE pathway. | ||||||
| Immune-marker response (mechanistic) | general | — | — | LimitedEvidencelimited | not assessed | PMID 24554461 |
| Mechanistic / immunomodulatory markers (cytokine response, NK-cell activity) have been reported in supporting laboratory and small-trial work but do not translate consistently into clinical cold-prevention or treatment outcomes per the Cochrane synthesis. "not_assessed" magnitude reflects that the clinically meaningful outcome (cold incidence/duration) is reported separately. | ||||||
Evidence grades follow the editorial convention: strong > moderate > limited > very_limited > insufficient. Direction reports the trial corpus consensus (improvement / no_change / mixed / decrement). Schema cross-emitted at MedicalSubstance.relevantClinicalCondition[].
Clinical literature review
The echinacea literature for common cold has been systematically reviewed in the Cochrane review Karsch-Völk 2014 CD000530 PMID 24554461 — 24 double-blind RCTs n=4,631 across multiple species (E. purpurea, E. angustifolia, E. pallida) and preparations (aerial parts, root, combined). Trial heterogeneity is substantial; preparation identification varies. Cochrane conclusion: Echinacea has not been shown to provide benefits for treating established colds, although weak benefit from some Echinacea products cannot be excluded; prophylaxis trials show consistent non-significant trends (post-hoc pooling RR reduction 10-20%). UK NICE CKS Common Cold pathway is symptomatic management; echinacea is not in the pathway. UK MHRA THR registration applies to specific traditional preparations with "long-standing use" evidence rather than RCT effectiveness data.
Key trials
Karsch-Völk M, Barrett B, Kiefer D, Bauer R, Ardjomand-Woelkart K, Linde K · 2014 · Cochrane Database Syst Rev (CD000530) · PMID 24554461
Finding: 24 double-blind RCTs comparing mono-preparations of Echinacea with placebo. 10 trials with 13 comparisons investigated prevention; 15 trials with 20 comparisons investigated treatment. Trial preparations varied across E. purpurea + E. angustifolia + E. pallida; aerial vs root parts. 10 trials had low risk of bias, 6 unclear, 8 high. None of the 12 prevention comparisons reporting cold-incidence reached statistical significance individually; post-hoc pooling suggested 10-20% RR reduction. Only 1 of 7 treatment trials reporting cold duration showed significant effect. Adverse events similar to placebo in prevention but with a trend toward more dropouts due to adverse events in treatment groups.
Relevance: The definitive evidence base for echinacea in common cold. Cochrane conclusion: products "have not been shown to provide benefits for treating colds, although it is possible there is a weak benefit from some Echinacea products". UK NICE CKS Common Cold does not include echinacea.
Systematic reviews
- pmid:24554461
Karsch-Völk 2014 Cochrane CD000530 — 24 RCTs n=4,631 — heterogeneous evidence with non-significant trend toward prevention benefit (post-hoc pooled RR reduction 10-20%); no consistent treatment benefit (1 of 7 trials).
Evidence quality summary
Common cold prevention — LIMITED certainty (Cochrane Karsch-Völk 2014 PMID 24554461 — heterogeneous trials, non-significant individual comparisons, post-hoc pooled 10-20% RR reduction). Common cold treatment of established symptoms — INSUFFICIENT certainty (Cochrane: only 1 of 7 trials showed significant duration reduction). UK MHRA THR registration — based on traditional use rather than RCT effectiveness. Asteraceae cross-reactivity safety — HIGH certainty for the allergy contraindication (substantial case-report literature).
Known gaps
- Standardised UK trials of THR-registered E. purpurea preparations (e.g., Echinaforce) in well-defined cold-prevention populations.
- Comparative trials of E. purpurea vs E. angustifolia vs E. pallida at matched alkamide / cichoric acid content.
- Long-term safety data beyond the 10-day THR-labelled limit.
- Genuine autoimmune-disease risk from echinacea (anecdotal-only case reports, no controlled data).
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
Echinacea is generally well-tolerated in adults without Asteraceae allergy, on a short-term acute basis (≤10 days). The realistic considerations are Asteraceae-family allergy (cross-reactive with ragweed, daisy, marigold, chamomile, feverfew), autoimmune- disease precaution, immunosuppressant interaction, and pregnancy avoidance for concentrated extracts.
Talk to your pharmacist or GP first if you:
- You have hay fever to ragweed / mugwort or known allergy to daisy, marigold, chamomile, or feverfew — Asteraceae cross-reactivity.
- You have diagnosed autoimmune disease (lupus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, autoimmune thyroid disease, IBD) — precautionary contraindication.
- You take an immunosuppressant (ciclosporin, tacrolimus, methotrexate, biologic DMARDs, mycophenolate) — theoretical antagonism.
- You are post-organ-transplant — avoid; transplant rejection risk.
- You take warfarin — modest in vitro CYP signals; disclose use.
- You are pregnant or breastfeeding — avoid concentrated supplement extracts.
- You are giving any supplement to a child — talk to GP / pharmacist; THR registrations exclude young children.
Common side effects: GI upset, mild rash, mouth itching. Allergic reactions in Asteraceae-sensitised individuals (urticaria, throat tightness, in rare cases anaphylaxis).
Pregnancy and breastfeeding
UK MHRA THR-registered echinacea product literature typically lists pregnancy as a contraindication. Avoid concentrated supplement extracts in pregnancy. Some traditional tea-tier use exists but is not the trial- evidenced pattern. Talk to your midwife or GP if you've been taking echinacea and are uncertain about a specific product.
UK MHRA THR-registered echinacea product literature typically lists breastfeeding as a contraindication. Talk to your midwife or health visitor before adding any echinacea product while breastfeeding.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Documented allergy to echinacea or other Asteraceae plants.
- Diagnosed autoimmune disease (lupus, rheumatoid arthritis, MS, type 1 diabetes, autoimmune thyroid disease, IBD) — precautionary.
- Concurrent immunosuppressant therapy (transplant, biologic DMARDs).
- Tuberculosis (historical traditional contraindication on the basis of immune-stimulation theoretical concern).
- Pregnancy and breastfeeding for concentrated supplement extracts.
- Children under 12 (UK MHRA THR registrations typically restrict).
Drug interactions
Immunosuppressants (ciclosporin, tacrolimus, methotrexate, mycophenolate, biologic DMARDs, JAK inhibitors) · high
Effect: Theoretical pharmacodynamic antagonism. Echinacea has documented in-vitro and animal-model immune-stimulating activity (macrophage / NK-cell activation, cytokine modulation); immunosuppressants suppress immune function as their therapeutic effect. The opposition is mechanism- plausible — and the consequence (rejection of transplant, flare of autoimmune disease) is potentially serious.
Mechanism: Echinacea alkamides + polysaccharides stimulate innate immunity (Dectin-1 / TLR2 / TLR4 signalling). Prescribed immunosuppressants reduce T-cell proliferation, B-cell antibody production, or specific cytokine pathways. The opposition is mechanism-plausible.
Action: Do NOT take echinacea if you are on immunosuppressant therapy for transplant, autoimmune disease, biologic DMARDs, or chemotherapy. Tell the team managing your immunosuppression about any echinacea-containing product (including combination cold-remedy products).
Source: BNF immunosuppressants + UK NICE pathway-specific guidance (NG129/NG130/NG225 etc.)
Warfarin — modest in vitro CYP signals; disclose use to anticoagulation clinic if you start an echinacea course while on stable warfarin dose.
CYP3A4 substrates (statins, calcium-channel blockers, oral contraceptives, etc.) — modest in vitro CYP3A4 inhibition signals; clinical relevance debated and likely modest at standard short-term echinacea doses.
CYP1A2 substrates (theophylline, caffeine, etc.) — modest in vitro effects.
Hepatotoxic medications (paracetamol at very high doses, methotrexate, amiodarone) — theoretical additive concern with rare case reports of liver-enzyme elevation on echinacea.
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- GI upset (nausea, abdominal cramping).
- Mild rash, mouth or throat itching.
- Unpleasant taste with tincture forms (alkamides produce a transient tongue tingle that some users find off-putting).
Rare side effects
- Allergic reactions: urticaria, contact dermatitis, throat tightness — Asteraceae-sensitised individuals.
- Anaphylaxis — rare but reported, particularly in highly Asteraceae-sensitised individuals.
- Theoretical autoimmune-disease exacerbation (case reports; causality uncertain).
- Mild liver-enzyme elevations (rare case reports).
How to take it
- Typical supplemental range
- UK MHRA THR-registered echinacea preparations have product- specific dosing — typically 200-900 mg/day of standardised E. purpurea root extract, or 5-10 drops of E. purpurea fresh-herb tincture (Echinaforce-style) 3× daily. Trial protocols typically dose for 7-10 days at first cold-symptom onset.
- Timing
- Acute use at first cold-symptom onset, continued 7-10 days. Three-times-daily dosing is most common in trial protocols. Some products offer prophylactic short-course dosing (e.g. Echinaforce 5-day prophylactic course) but the bulk of evidence is acute / treatment.
How to spot quality
Look for
- Plant species declared (E. purpurea, E. angustifolia, E. pallida) AND plant part (root, aerial parts, whole plant).
- MHRA THR licence number on the pack ("THR XXXXX/XXXX") for traditional-use registered products.
- Standardisation declared: cichoric acid % (E. purpurea aerial parts), alkamide % (root), echinacoside % (E. angustifolia / E. pallida root).
- Extraction method declared (fresh-herb pressed-juice, aqueous-ethanolic tincture, dried-herb capsule).
- Asteraceae-allergy warning visible on the pack.
- Short-term-use guidance visible (≤10 days continuous, with rest period before re-starting).
- GMP-certified manufacture.
Red flags
- No species declaration ("echinacea" without genus and species).
- No plant-part declaration (root vs aerial differ in chemotype).
- No MHRA THR licence number on a product positioned for cold / immune indications.
- No Asteraceae-allergy warning.
- Marketing for chronic / daily immune support — outside THR registration scope.
- Marketing for autoimmune-disease "support" or autoimmune-symptom management.
- Marketing for paediatric self-supplementation.
- Combination products with kava (banned in UK as a food supplement).
Where Camden lands · meets the bar
Camden Medicals does not currently retail a single-active echinacea SKU. The category is well-served by UK MHRA THR-registered preparations (A. Vogel Echinaforce® being the most-trialled), and Camden's editorial position is that THR-registered products with declared species + plant-part + standardisation are the right tier for acute cold-symptom use. If we evaluate an echinacea SKU in future, entry conditions are: declared species (E. purpurea, E. angustifolia, or E. pallida), declared plant part (root vs aerial), declared standardisation marker (cichoric acid % or alkamide %), Asteraceae-allergy warning visible on label, short-term-use guidance on label (≤10 days continuous, ≥3 weeks rest before re-starting), and MHRA THR licence number where the product makes cold / immune indications.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Elderberry (Sambucus nigra, Black Elder)
Limited evidenceThe most common UK acute-cold herbal pairing — echinacea immune-modulation + elderberry antiviral signal in a single short-course product.
Echinacea (alkamides + cichoric acid + polysaccharides) modulates innate immune cell function — macrophage cytokine release, dendritic-cell maturation, NK-cell activity — across multiple axes. Elderberry (Sambucus nigra) provides anthocyanin-rich extract with documented in-vitro antiviral activity against influenza A, influenza B, and several rhinoviruses, plus immune-modulating effect via cytokine signalling.
The combination is mechanism-complementary: echinacea on the immune-cell-modulation axis, elderberry on the antiviral axis. The combination appears in many UK acute-cold products (A. Vogel Echinaforce® Cold & Flu, Sambucol Plus, Beauty & Go Immune, similar) often alongside zinc and vitamin C.
Trial evidence on the specific echinacea-elderberry combination is small; each component has its own trial body. UK NHS first-line for acute cold remains rest, fluids, simple analgesia. UK NICE pathway does not list either.
Evidence: Combined echinacea-elderberry trials are small. Individual Cochrane reviews exist for echinacea (Karsch-Völk 2014); elderberry systematic reviews (Tiralongo / Hawkins 2020) support modest benefit in upper-respiratory symptom duration. [5]
Doses studied: Echinacea purpurea standardised extract 200-500 mg + Sambucus nigra extract 300-600 mg (15-30% anthocyanins), 7-10 day acute course at first cold-symptom onset.
Vitamin C
Limited evidenceAuthorised-claim anchor for an echinacea cold product — vitamin C provides the UK Article 13.1 authorised immune claim that echinacea cannot.
Vitamin C is required for normal immune-cell function (neutrophil chemotaxis, lymphocyte proliferation) and carries the UK Article 13.1 authorised claim "Vitamin C contributes to the normal function of the immune system" at intakes above the 12 mg NRV trigger. Echinacea's immune-modulation mechanism via alkamides and polysaccharides is independent of vitamin C.
The pairing is regulatory-strategic: a UK echinacea-plus-vitamin-C product can carry the vitamin-C authorised immune claim on the front of the pack, while the echinacea component sits in the THR or food-supplement tier without an authorised claim. The trial evidence does not show synergy specifically — each component has its own trial body. Hemilä's Cochrane review on vitamin C and the common cold is more positive in athletes / cold-stressed populations than in the general public; routine vitamin-C supplementation does not reduce cold incidence in the general population at standard doses.
Evidence: Vitamin C UK Article 13.1 immune claim authorised (gb-nhc:vitamin_c). Combination trials small. [9]
Doses studied: Echinacea purpurea extract 200-500 mg + vitamin C 80-1000 mg per dose, daily for 7-10 day acute-cold course.
Zinc
Limited evidenceAcute-cold cluster pairing — echinacea immune-modulation + zinc anti-rhinoviral activity for cold-symptom duration.
Zinc lozenges (zinc gluconate or zinc acetate at 75-100 mg/day in divided doses across the day) have Cochrane review support (Hemilä 2017) for reducing common-cold duration when started within 24 hours of symptom onset — mechanism is direct antiviral effect against rhinovirus replication in the upper respiratory tract via zinc binding to the rhinovirus 3C-protease. Zinc also carries the UK Article 13.1 authorised claim "Zinc contributes to the normal function of the immune system".
Echinacea acts on the immune-modulation axis (alkamides, polysaccharides). The combination is mechanism-additive: zinc on the antiviral axis, echinacea on the immune-modulation axis. Combination trials are small but the each-component trial bases support short-course acute-cold use. The combination appears in many UK cold-symptom lozenges and effervescent tablets (alongside vitamin C).
Evidence: Zinc lozenges have Cochrane support for cold-symptom duration (Hemilä). Echinacea Cochrane evidence is mixed. UK Article 13.1 authorised immune claims for both zinc and vitamin C. [9]
Doses studied: Echinacea purpurea extract 200-500 mg + zinc gluconate 10-25 mg per dose (high-dose zinc gluconate / acetate 75-100 mg/day in divided lozenge doses for the cold-duration effect), 7-10 day acute course.
Saccharomyces boulardii
Insufficient evidenceGut-immune axis pairing — echinacea innate-immune modulation alongside S. boulardii probiotic gut-mucosal effect for broader immune-system framing.
S. boulardii is a yeast probiotic with documented gut-immune-axis effect — modulates intestinal IgA secretion, dendritic-cell function in the gut-associated lymphoid tissue (GALT), and brush-border enzyme expression. Echinacea works on systemic innate-immune cells via alkamides and polysaccharides.
The combination is mechanism-complementary: probiotic on the gut-immune axis, echinacea on the systemic innate-immune axis. Trial evidence on the combination is limited; each component has its own trial body. Note that S. boulardii is a live-yeast probiotic and is contraindicated in immunosuppressed individuals (transplant patients, biologic DMARDs) for the separate reason of fungaemia risk — the two ingredients share the immunosuppressant contraindication context.
Evidence: Mechanism complementary; combination trials essentially absent.
Doses studied: Echinacea purpurea extract 200-500 mg + S. boulardii 250-1000 mg/day, 7-10 day acute course or as part of broader gut-immune supplementation.
Verifera™ editorial perspective
Why it matters. Echinacea is one of the most-marketed UK cold-and-flu botanicals — sold widely as a THR-registered traditional herbal medicine and as broader food-supplement preparations. Consumer marketing frequently overstates the Cochrane evidence base (which is genuinely mixed at best) and under-discloses the Asteraceae-allergy and autoimmune- disease precautionary contraindications. The Verifera editorial position is to honestly surface both the Karsch-Völk 2014 PMID 24554461 mixed-evidence summary and the load-bearing safety messages.
Where Camden lands. Camden Medicals does NOT currently retail single-active echinacea SKUs. The entry serves as the immune-cluster botanical reference alongside Camden's elderberry + milk-thistle entries (the Wave-15 Batch 6 Asteraceae cluster). For UK consumers researching this space: a UK THR-registered Echinacea purpurea product (A. Vogel Echinaforce or similar) is the controlled-quality route; species identification on the label is the minimum quality bar; ≤10 days continuous use per THR labelling; Asteraceae allergy is a hard contraindication.
If you want to explore further. For uncomplicated viral upper-respiratory infections: UK NHS pathway is rest, hydration, paracetamol / ibuprofen for symptoms — no specific antiviral or herbal intervention has strong evidence. If you choose to try echinacea: UK THR-registered E. purpurea product, taken at first onset of symptoms for ≤10 days continuous use; check Asteraceae allergy history first; do not use if you have autoimmune disease without specialist input; not during pregnancy or breastfeeding. Children <12 (some products <18): not appropriate.
How this entry was researched
Authoritative sources consulted:
- NHS Common cold + Cold sore + Sore throat pages
- NICE CKS Common cold + Influenza
- MHRA Traditional Herbal Registrations register (Echinaforce, related products)
- BHMA Herbal Compendium (Echinacea monograph)
- EMA HMPC Echinacea purpurea community monograph
- GB Nutrition and Health Claims (NHC) Register (no authorised echinacea claim outside MHRA THR)
- Cochrane Database (Karsch-Völk 2014 CD000530)
- PubMed (via E-utilities MCP, 2026-05-12)
PubMed search terms:
Karsch-Volk Echinacea common cold Cochrane systematic reviewechinacea cold prevention systematic review meta-analysis randomized
Literature search date: 2026-05-12
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.